Nicotinamide attenuates aquaporin 3 overexpression induced by retinoic acid through inhibition of EGFR/ERK in cultured human skin keratinocytes.
The most common adverse effects that are related to all-trans retinoic acid (atRA) treatment are irritation and dryness of the skin. atRA therapy is reported to impair barrier function as achieved by trans-epidermal water loss (TEWL). Treatment with nicotinamide prior to initiation of atRA therapy provides additional barrier protection and thus reduces susceptibility of retinoic acid. Our previous studies showed that atRA upregulates aquaporin 3 (AQP3) in cultured human skin keratinocytes and fibroblasts. Others have demonstrated that in atopic dermatitis, overexpression of AQP3 is linked to elevated TEWL and that nicotinamide treatment reduces skin TEWL. In this study, we observed that while atRA upregulates AQP3 expression in cultured human skin keratinocytes (HaCaT cells), nicotinamide attenuates the effect of atRA in a concentration-dependent manner. atRA treatment induces EGFR and ERK activation. PD153035, an EGFR inhibitor, and U0126, an ERK inhibitor, inhibit atRA-induced upregulation of AQP3. Nicotinamide also inhibits atRA-induced activation of EGFR/ERK signal transduction and decreases water permeability by downregulating AQP3 expression. Collectively, our results indicate that the effect of atRA on AQP3 expression is at least partly mediated by EGFR/ERK signaling in cultured human skin keratinocytes. Nicotinamide attenuates atRA-induced AQP3 expression through inhibition of EGFR/ERK signal transduction and eventually decreases water permeability and water loss. Our study provides insights into the molecular mechanism through which nicotinamide reverses the side effects of dryness in human skin after treatment with atRA.
Song
Xiuzu
X
Department of Dermatology, the Third Hospital of Hangzhou, Hangzhou, PR China.
Xu
Aie
A
Pan
Wei
W
Wallin
Brittany
B
Kivlin
Rebecca
R
Lu
Shan
S
Cao
Cong
C
Bi
Zhigang
Z
Wan
Yinsheng
Y
D000818:Animals; D051400:Aquaporin 3 / Q000235:genetics / Q000378:metabolism*; D002478:Cells, Cultured; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism*; D007641:Keratolytic Agents / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000502:physiology; D009536:Niacinamide / Q000494:pharmacology*; D010539:Permeability; D034622:RNA Interference; D012867:Skin / Q000166:cytology; D014212:Tretinoin / Q000494:pharmacology*; D014803:Vitamin B Complex / Q000378:metabolism
D007641:Keratolytic Agents; D014803:Vitamin B Complex; D051400:Aquaporin 3; D009536:Niacinamide; D014212:Tretinoin; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D048049:Extracellular Signal-Regulated MAP Kinases